SciSparc Announces Positive Topline Results For Proprietary Pain Management Compound In Pre-Clinical Study
Cannabis Law Report
AUGUST 2, 2021
(OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain.
Let's personalize your content